Sidetrade financial calendar 2025 , the global leader in AI-powered Order-to-Cash applications, today announces its 2025 financial calendar. Annual Revenue for 2024Tuesday 21 January 2025 after stock market closes Annual Results for 2024Wednesday 26 March 2025 after stock market closes First Quarter Revenue for 2025Tuesday 15 April 2025 after stock market closes Annual Shareholder general meeting 2025Wednesday 18 June 2025 from 11:00am (CEST) First Half Year Revenue for 2025Wednesday 16 July 2025 after stock market closes First Half Year Results for 2025Wednesday 17 September 2025...
Eramet: Purchase of own shares Paris, 18 November 2024, 6:00 p.m. PRESS RELEASE Eramet: Purchase of own shares Eramet announces the purchase of 9,900 of its own shares related to the allocation of bonus shares under the provisions of Articles L. 225-197-1 et seq. and L. 22-10-59 and L. 22-10-60 of the French Commercial Code (to cover the free allocation of shares to employees and corporate officer). Aggregated presentation per day and per market Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instru...
>Halozyme sees a good fit for both of Evotec’s business units - Halozyme Therapeutics, Inc. confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE to acquire Evotec for € 11.00 per share in cash, implying a fully diluted equity value of € 2.0bn. The proposal represents a premium of 27% to yesterday’s closing price and a premium of 77% to Evotec's last three-month volume weighted average price on 15 October 2024, th...
>Q3 below expectations due to weak manganese and nickel volumes - Eramet released Q3 sales of € 809m, down 17% YoY and below our estimates due to weak volumes in its main activities.In the Manganese division, the exceptionally favourable environment stemming from the suspension of the Gemco mine in March has moved against the group. In attempting to impose prices that were too high in a Chinese context depressed by falling steel production, alloy makers were enco...
>T3 inférieur aux attentes à cause de volumes faibles sur le manganèse et le nickel - Eramet a publié un CA T3 de 809 M€, en recul de 17% vs 2023 et sous nos attentes à cause de la faiblesse des volumes dans les deux principales activités.Dans la division Manganèse, l’environnement exceptionnellement favorable issu de la suspension de la mine de Gemco en mars s’est complètement retourné contre le groupe. En tentant d’imposer des prix trop élevés dans un contexte ...
>Q3 2024 sales 3.6% higher than our above-market expectation - B&S Group reported a solid Q3 2024, in our view. Sales came in 3.6% higher than our estimate, which we think was the highest in the market. In all divisions except retail, organic sales growth was either higher than expected or significantly better than forecast. Management’s tone on the business was generally positive, and the same applies to the comments about Q4 2024. We forecast 7.1% sales growth in Q4...
The B&S 3Q24 trading update surprised positively on top line performance but disappointed somewhat on costs. 3Q24 revenue was c.8% above our expectations and growth was driven by most business segments. B&S indicated that gross margin decreased in 3Q24, while we expected flat YoY gross margin. Wage costs also increased, this in line with management expectations and our own. As a consequence B&S expects FY24 EBITDA margin to be in the lower half of the 5-6% guidance. We raise our FY24 revenue est...
Die Trendwende deutet sich an. Die Q3-KPIs zeigen erste Umsatz- und Margen-Erholung, denn Kapazitäten steigen und die „Reset“-Sanierungen beginnt Früchte zu tragen (Q3/24: Umsatz €185 +1,5%; EPS € -0,22 (Q3/23: € -0,22)). Der Liquiditätsabfluss ist in Q3 gestoppt. Doch die allgemeine Orderentwicklung ist noch von Zurückhaltung geprägt. Q4/24 soll (projektgetrieben) ein starkes Quartal (inkl. Reset-Einsparungen) werden - die 24er Guidance wird bestätigt.
Springer Nature is one of the world’s leading professional publishing companies. Its highly recurring revenue base and strong market position, good FCF generation and a deleveraging balance sheet should lead to a rerating, we believe. We initiate coverage with an Outperform and a TP of €33. - ...
Springer Nature is one of the world’s leading professional publishing companies. Its highly recurring revenue base and strong market position, good FCF generation and a deleveraging balance sheet should lead to a rerating, we believe. We initiate coverage with an Outperform and a TP of €33. - ...
>Sales beat expectations in Q3 2024; gross margin under pressure - B&S Group reported net sales of € 609.1m in Q3 2024. Organic sales growth amounted to 11.8% in the quarter. Our estimates were € 588m and 7.8%, respectively. There was no consensus available, but from investors we understood that our estimates were the highest. All segment, except the retail segment, strongly outperformed our forecasts. Management added that turnover increased across all segments, whil...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.